Biodesix, Inc. (BDSX)

NGM – Real Time Price. Currency in USD

15.75

-0.36 (-2.23%)

At close: May 12, 2026, 4:00 PM EDT

15.96

+0.21 (1.33%)

Pre-market: May 13, 2026, 8:22 AM EDT

11.05.2026

Biodesix Announces ATS 2026 Presentations Providing Real-World Clinical Evidence and Healthcare System Economic Value for Nodify Lung® Testing Strategy

Includes real-world clinical data from Biodesix researchers and independent Healthcare Professionals Includes real-world clinical data from Biodesix researchers and independent Healthcare Professionals

07.05.2026

Does Biodesix (BDSX) Have the Potential to Rally 103.33% as Wall Street Analysts Expect?

The mean of analysts' price targets for Biodesix (BDSX) points to a 103.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

04.05.2026

Biodesix, Inc. (BDSX) Q1 2026 Earnings Call Transcript

04.05.2026

Biodesix, Inc. (BDSX) Reports Q1 Loss, Tops Revenue Estimates

Biodesix, Inc. (BDSX) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $1.26. This compares to a loss of $1.6 per share a year ago.

04.05.2026

Biodesix Announces First Quarter 2026 Results and Highlights

Delivered $25.6 million in revenue representing 42% growth in Q1 2026; Achieved 84% gross margin in Q1 2026; Increased FY 2026 Revenue Guidance to $108-114 million, mid-point reflects 25% growth; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo.

20.04.2026

Biodesix to Report First Quarter 2026 Financial Results on May 4, 2026

LOUISVILLE, Colo., April 20, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the first quarter ended March 31, 2026 after the close of trading on Monday, May 4. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.

09.04.2026

Biodesix Recognized as a Top Workplace for Third Consecutive Year

Employee-Driven, Prestigious National Recognition for the Consistently High-Performing Biodesix Culture Employee-Driven, Prestigious National Recognition for the Consistently High-Performing Biodesix Culture

Videos

No Data

There is no data to display

Press releases

11.05.2026

Biodesix Announces ATS 2026 Presentations Providing Real-World Clinical Evidence and Healthcare System Economic Value for Nodify Lung® Testing Strategy

04.05.2026

Biodesix Announces First Quarter 2026 Results and Highlights

09.04.2026

Biodesix Recognized as a Top Workplace for Third Consecutive Year

06.04.2026

Biodesix Announces AACR 2026 Posters and Presentations, Highlighting Novel Diagnostic Test Discovery & Pipeline Development

Includes novel proteomic and genomic approaches to oncology therapeutic selection, response monitoring, and Molecular Residual Disease (MRD) testing Includes novel proteomic and genomic approaches to oncology therapeutic selection, response monitoring, and Molecular Residual Disease (MRD) testing

Biodesix, Inc. (BDSX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Biodesix, Inc. (BDSX)

Biodesix Announces ATS 2026 Presentations Providing Real-World Clinical Evidence and Healthcare System Economic Value for Nodify Lung® Testing Strategy

Does Biodesix (BDSX) Have the Potential to Rally 103.33% as Wall Street Analysts Expect?

Biodesix, Inc. (BDSX) Q1 2026 Earnings Call Transcript

Biodesix, Inc. (BDSX) Reports Q1 Loss, Tops Revenue Estimates

Biodesix Announces First Quarter 2026 Results and Highlights

Biodesix to Report First Quarter 2026 Financial Results on May 4, 2026

Biodesix Recognized as a Top Workplace for Third Consecutive Year

Videos

No Data

Press releases

Biodesix Announces ATS 2026 Presentations Providing Real-World Clinical Evidence and Healthcare System Economic Value for Nodify Lung® Testing Strategy

Biodesix Announces First Quarter 2026 Results and Highlights

Biodesix Recognized as a Top Workplace for Third Consecutive Year

Biodesix Announces AACR 2026 Posters and Presentations, Highlighting Novel Diagnostic Test Discovery & Pipeline Development

Biodesix Announces ATS 2026 Presentations Providing Real-World Clinical Evidence and Healthcare System Economic Value for Nodify Lung® Testing Strategy

Does Biodesix (BDSX) Have the Potential to Rally 103.33% as Wall Street Analysts Expect?

Biodesix, Inc. (BDSX) Q1 2026 Earnings Call Transcript

Biodesix, Inc. (BDSX) Reports Q1 Loss, Tops Revenue Estimates

Biodesix Announces First Quarter 2026 Results and Highlights

Biodesix to Report First Quarter 2026 Financial Results on May 4, 2026

Biodesix Recognized as a Top Workplace for Third Consecutive Year

Videos

No Data

Press releases

Biodesix Announces ATS 2026 Presentations Providing Real-World Clinical Evidence and Healthcare System Economic Value for Nodify Lung® Testing Strategy

Biodesix Announces First Quarter 2026 Results and Highlights

Biodesix Recognized as a Top Workplace for Third Consecutive Year

Biodesix Announces AACR 2026 Posters and Presentations, Highlighting Novel Diagnostic Test Discovery & Pipeline Development

Search stocks

Biodesix, Inc. (BDSX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Biodesix, Inc. (BDSX)

Biodesix Announces ATS 2026 Presentations Providing Real-World Clinical Evidence and Healthcare System Economic Value for Nodify Lung® Testing Strategy

Does Biodesix (BDSX) Have the Potential to Rally 103.33% as Wall Street Analysts Expect?

Biodesix, Inc. (BDSX) Q1 2026 Earnings Call Transcript

Biodesix, Inc. (BDSX) Reports Q1 Loss, Tops Revenue Estimates

Biodesix Announces First Quarter 2026 Results and Highlights

Biodesix to Report First Quarter 2026 Financial Results on May 4, 2026

Biodesix Recognized as a Top Workplace for Third Consecutive Year

Videos

No Data

Press releases

Biodesix Announces ATS 2026 Presentations Providing Real-World Clinical Evidence and Healthcare System Economic Value for Nodify Lung® Testing Strategy

Biodesix Announces First Quarter 2026 Results and Highlights

Biodesix Recognized as a Top Workplace for Third Consecutive Year

Biodesix Announces AACR 2026 Posters and Presentations, Highlighting Novel Diagnostic Test Discovery & Pipeline Development

Biodesix Announces ATS 2026 Presentations Providing Real-World Clinical Evidence and Healthcare System Economic Value for Nodify Lung® Testing Strategy

Does Biodesix (BDSX) Have the Potential to Rally 103.33% as Wall Street Analysts Expect?

Biodesix, Inc. (BDSX) Q1 2026 Earnings Call Transcript

Biodesix, Inc. (BDSX) Reports Q1 Loss, Tops Revenue Estimates

Biodesix Announces First Quarter 2026 Results and Highlights

Biodesix to Report First Quarter 2026 Financial Results on May 4, 2026

Biodesix Recognized as a Top Workplace for Third Consecutive Year

Videos

No Data

Press releases

Biodesix Announces ATS 2026 Presentations Providing Real-World Clinical Evidence and Healthcare System Economic Value for Nodify Lung® Testing Strategy

Biodesix Announces First Quarter 2026 Results and Highlights

Biodesix Recognized as a Top Workplace for Third Consecutive Year

Biodesix Announces AACR 2026 Posters and Presentations, Highlighting Novel Diagnostic Test Discovery & Pipeline Development